17 results
Thumbnail

D1.396 - Drug hypersensitivity reactions in paediatric patients pre and post-liver transplant: a single-center study

Thumbnail

D1.394 - Functional AOC1 variants associated with reduced diamine oxidase activity mimicking multiple drug hypersensitivity and mast cell disorders

Thumbnail

D1.397 - Successfull rapid drug desensitization to cemiplimab in a patient with lung squamous cell carcinoma

Thumbnail

D1.398 - Safety Outcomes and Predictors of Clinically Significant Reactions in Positive Drug Provocation Tests: A 10-Year Tertiary-Center Cohort

Thumbnail

D1.399 - Selective IgE Mediated Anaphylaxis to Gadobutrol and type I Kounis with tolerance to Gadoxetate Disodium

Thumbnail

D1.400 - Omalizumab premedication improves ferric carboxymaltose desensitization outcomes: A Case Report

Thumbnail

D1.401 - Progression from Immediate to Delayed Hypersensitivity: A Rare Case of Iodixanol-Induced Acute Generalised Exanthematous Pustulosis

Thumbnail

D1.402 - Angiotensin-Converting Enzyme Inhibitor–Induced Bradykinin-Mediated Angioedema: Three Cases of Sustained Remission Following Definitive Discontinuation and the Critical Role of the Prescribing Physician

Thumbnail

D3.166 - Attention-deficit/hyperactivity disorder (ADHD) in asthmatic children

Thumbnail

D3.168 - Clinical Department of Allergy Center in Linköping

Thumbnail

D3.169 - Paediatric Severe Acute Respiratory Infections in Malta: A Three-Year Review

Thumbnail

D3.171 - Validation of the Kazakh Version of the Asthma Quality of Life Questionnaire (AQLQ) for Clinical Use in Adult Patients with Asthma

Thumbnail

D3.173 - Switching from Dupilumab to Tezepelumab in a Child with Severe Asthma and Atopic Dermatitis: Clinical Considerations and Therapeutic Implications

Thumbnail

D3.174 - Short-term tolerance of omlyclo, the omalizumab biosimilar

Thumbnail

D3.175 - Algorithm for Biologics Selection in Severe Asthma

Thumbnail

D3.178 - Assessment of blood rheological properties in children with bronchial asthma

Thumbnail

D3.179 - Longitudinal breath profiling of exhaled volatile organic compounds differentiates viral-induced asthma exacerbation from clinical control